BioLineRx Ltd. Share Price TEL AVIV STOCK EXCHANGE
Equities
BLRX
IL0011015182
Biotechnology & Medical Research
Sales 2024 * | 17.57M 65.75M 1.39B | Sales 2025 * | 29.87M 112M 2.36B | Capitalization | 52.58M 197M 4.15B |
---|---|---|---|---|---|
Net income 2024 * | -35M -131M -2.76B | Net income 2025 * | -16M -59.88M -1.26B | EV / Sales 2024 * | 2.99 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.76 x |
P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
Latest transcript on BioLineRx Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 23/05/09 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 31/12/08 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 23/02/14 |
Avraham Molcho
BRD | Director/Board Member | 66 | 31/12/09 |
Aharon Schwartz
CHM | Chairman | 80 | 31/12/03 |
1st Jan change | Capi. | |
---|---|---|
+16.45% | 122B | |
+21.96% | 116B | |
+25.44% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-16.47% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |